Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michiel Vlaming

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cancer Treatment and Research Communications|December 14, 2020
Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancerMichiel Vlaming, Lambertus A L M Kiemeney, Antoine G van der Heijden
BMC Cancer|December 29, 2022
Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational studyMichiel Vlaming, Eveline M A Bleiker, Inge M van Oort, et al.
Critical Reviews in Oncology/Hematology|November 12, 2025
AI-based prediction of molecular aberrations in prostate cancer using digital pathology: A systematic reviewJacqueline E van Hees, Michiel Vlaming, Rachel N Flach, et al.
Cancers|February 25, 2022
The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic ReviewKyra Bokkers, Michiel Vlaming, Ellen G Engelhardt, et al.
British Journal of Cancer|October 3, 2022
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patientsLourdes Mengual, Maria Frantzi, Marika Mokou, et al.
Familial Cancer|May 9, 2024
Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relativesMichiel Vlaming, Margreet G E M Ausems, Gina Schijven, et al.
BJU International|September 2, 2025
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancerMichiel Vlaming, Wouter Koole, R Jeroen A van Moorselaar, et al.
Prostate Cancer and Prostatic Diseases|December 5, 2024
Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancerMichiel Vlaming, Margreet G E M Ausems, Lambertus A L M Kiemeney, et al.
International Journal of Cancer|October 13, 2025
Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathwayMichiel Vlaming, Eveline M A Bleiker, Gina Schijven, et al.
European Urology Open Science|March 6, 2023
Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus MeetingNiven Mehra, Iris Kloots, Michiel Vlaming, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancer Treatment and Research Communications|December 14, 2020
Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancerMichiel Vlaming, Lambertus A L M Kiemeney, Antoine G van der Heijden
BMC Cancer|December 29, 2022
Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational studyMichiel Vlaming, Eveline M A Bleiker, Inge M van Oort, et al.
Critical Reviews in Oncology/Hematology|November 12, 2025
AI-based prediction of molecular aberrations in prostate cancer using digital pathology: A systematic reviewJacqueline E van Hees, Michiel Vlaming, Rachel N Flach, et al.
Cancers|February 25, 2022
The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic ReviewKyra Bokkers, Michiel Vlaming, Ellen G Engelhardt, et al.
British Journal of Cancer|October 3, 2022
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patientsLourdes Mengual, Maria Frantzi, Marika Mokou, et al.
Familial Cancer|May 9, 2024
Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relativesMichiel Vlaming, Margreet G E M Ausems, Gina Schijven, et al.
BJU International|September 2, 2025
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancerMichiel Vlaming, Wouter Koole, R Jeroen A van Moorselaar, et al.
Prostate Cancer and Prostatic Diseases|December 5, 2024
Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancerMichiel Vlaming, Margreet G E M Ausems, Lambertus A L M Kiemeney, et al.
International Journal of Cancer|October 13, 2025
Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathwayMichiel Vlaming, Eveline M A Bleiker, Gina Schijven, et al.
European Urology Open Science|March 6, 2023
Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus MeetingNiven Mehra, Iris Kloots, Michiel Vlaming, et al.
Pageof 2